Sugammadex Vs Neostigmine/glycopyrrolate on Urinary Retention After Spine Surgery

Launched by UNIVERSITY OF MISSOURI-COLUMBIA · May 24, 2023

Keywords

ClinConnect Summary

Subjects requiring elective ambulatory posterior lumbar laminectomy, will receive either an intravenous infusion bolus of Sugammadex (2 mg/kg dosed by actual body weight) or intravenous infusion bolus of Neostigmine (50 μg/kg, up to 5 mg maximum dose) plus Glycopyrrolate (10 μg/kg, up to 1 mg maximum dose). Additionally, all subjects will receive hospital standard of care therapy for their surgery and hospital stay.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • ASA Physical Status I-III
• Exclusion Criteria:
• • Inability to obtain written informed consent
• • Allergy to medications used in the protocol
• • Known or suspected neuromuscular disorders
• • Significant renal disease with a serum creatinine ≥ 2 mg/dL
• • Significant liver disease
• • A family history of malignant hyperthermia
• • History of genitourinary surgery, cancer, or radiation within the last year
• • Currently prescribed urological medications or diuretics
• • BPH or symptoms of BPH (interrupted or weak urine stream or wake up to urinate more than two times per night)
• • History or diagnosis of urinary incontinence or urinary retention
• • History of PONV with use of scopolamine
• • Use of Foley catheter pre- or intra- operatively
• • Perioperative medications that influence micturition (e.g., diuretics or intraoperative anticholinergic medication use other than NMB reversal)